Vol 9, No 3 (2018)
Review paper
Published online: 2018-10-17
Significance of minimal residual disease evaluation in AL amyloidosis
Hematologia 2018;9(3):196-201.
Abstract
Light chain amyloidosis (AL amyloidosis) is a systemic disease leading to organ damage due to deposition of amyloid fibers arising from accumulation of amyloid precursors – monoclonal immunoglobulin light chains produced by clonal bone marrow plasmocytes. The aim of AL amyloidosis therapy is the inhibition amyloidogenic immunoglobulin light chains, what should result in stabilization or often even improvement of involved organs’ function. Treatment effectiveness evaluation is based on hematological and organ response. Despite achievement of complete hematological remission, in some of the patients even a trace number of plasmocytes persisting following treatment may lead to production of low amount of monoclonal immunoglobulins capable of deepening organ damage. These plasmocytes remain undetectable to routine diagnostic approaches and are regarded as minimal residual disease (MRD). Considering the results of the so far published research, it is possible that MRD assessment based on flow cytometric technique may constitute a basic tool of response assessment of AL amyloidosis treatment in the future. In this publication the methodology and results of latest research concerning MRD assessment in AL amyloidosis are presented.
Keywords: amyloidosisminimal residual diseaseflow cytometry
References
- Jamroziak K, Milani P, Puła B, et al. Diagnostyka i leczenie amyloidozy AL. Hematologia. 2018; 9(3): XX–XX.
- Perfetti V, Colli Vignarelli M, Anesi E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica. 1999; 84(3): 218–221.
- Lisenko K, Schönland SO, Jauch A, et al. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis. Cancer Med. 2016; 5(7): 1464–1472.
- Flores-Montero J, de Tute R, Paiva B, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016; 90(1): 61–72.
- Jamroziak K, Krzywdzińska A, Solarska I, et al. Znaczenie minimalnej choroby resztkowej w szpiczaku plazmocytowym — Stanowisko Polskiego Konsorcjum Szpiczakowego. Hematologia. 2018; 8(4): 246–254.
- Landgren O, Devlin S, Boulad M, et al. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant. 2016; 51(12): 1565–1568.
- Lahuerta JJ, Paiva B, Vidriales MB, et al. GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017; 35(25): 2900–2910.
- Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8): e328–e346.
- Oldaker TA, Wallace PK, Barnett D. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma. Cytometry B Clin Cytom. 2016; 90(1): 40–46.
- Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017; 31(10): 2094–2103.
- Krzywdzińska A, Solarska I, Puła B, et al. Minimal residual disease assessment in plasma cell myeloma patients in Poland: survey of the Polish Myeloma Consortium. Hematologia. 2017; 8(4): 246–254.
- Paiva B, Vídriales MB, Pérez JJ, et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood. 2011; 117(13): 3613–3616.
- Muchtar E, Jevremovic D, Dispenzieri A, et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood. 2017; 129(1): 82–87.
- Sachchithanantham S, Baginska A, Rowczenio D, et al. Use of plasma cell immunophenotype as prognostic markers in patients with systemic AL amyloidosis. Blood. 2013; 122(21): 3120–3120.
- Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012; 30(36): 4541–4549.
- Dispenzieri A, Buadi F, Kumar SK, et al. Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015; 90(8): 1054–1081.
- Jimenez-Zepeda V, Duggan P, Neri P, et al. Minimal residual disease (MRD) assessed by flow cytometry in patients with AL amyloidosis treated with cyclophosphamide, bortezomib and dexamethasone (CyBorD). Blood. 2017; 130(Suppl 1): 1836–1836.
- Sidiqi MH, Aljama MA, Jevremovic D, et al. Prognostic significance of stringent complete response after stem cell transplantation in immunoglobulin light chain amyloidosis. Biol Blood Marrow Transplant. 2018 [Epub ahead of print].
- Palladini G, Massa M, Basset M, et al. Persistence of minimal residual disease by multiparameter flow cytometry can hinder recovery of organ damage in patients with AL amyloidosis otherwise in complete response. Blood. 2016; 128(22): 3261–3261.
- Sidana S, Tandon N, Dispenzieri A, et al. The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. Leukemia. 2018; 32(5): 1243–1246.
- Kastritis E, Kostopoulos IV, Terpos E, et al. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018; 8(5): 46.
- Gonsalves WI, Rajkumar SV, Dispenzieri A, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017; 31(1): 130–135.
- Gonsalves WI, Rajkumar SV, Gupta V, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 2014; 28(10): 2060–2065.
- Sidana S, Tandon N, Dispenzieri A, et al. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia. 2018; 32(6): 1421–1426.
